Update on resistance in Gram-positive cocci

15:30 • 1959 • Populational structure and evolutionary scenario of the multidrug-resistant pathogen <em>Enterococcus faecium</em> in hospitals of Rio de Janeiro, Brazil > S. Stephanie SOUZA (Rio De Janeiro) 15:40 • 1031 • Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalised with skin structure infections in Europe and North American medical centres: results from the International Dalbavancin Evaluation of Activity (IDEA) programme (2019-2020) > H. Helio S. SADER (North Liberty) 15:50 • 2366 • <em>In vitro</em> activity of ceftaroline plus daptomycin or fosfomycin against methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) > D. Daniel Antonio VÁZQUEZ-SÁNCHEZ (L'hospitalet De Llobregat) 16:00 • 393 • <em>In vitro</em> activity of dalbavancin against glycopeptide-resistant <em>Enterococcus faecium</em> and coagulase-negative staphylococci recovered from patients in Germany > M. Michael KRESKEN (Cologne) 16:10 • 4458 • Molecular mechanisms of linezolid resistance among <em>Staphylococcus </em>spp. and <em>Enterococcus </em>spp. recovered in a Spanish hospital > I. Idris Nasir ABDULLAHI (Logroño) 16:20 • 1915 • Development and validation of a clinical score for the prediction of vancomycin-resistant enterococci (VRE) persistence in VRE colonised patients > C. Christian Wilhelm BÖING (Münster (North Rhine-Westphalia)) 16:30 • 3204 • Truncated EfrEF operons highly limit the growth of human ST40 <em>Enterococcus faecalis</em> populations under chlorhexidine stress > A. Ana Paula PEREIRA (Porto) 16:40 • INT76 • Q&A/Discussion